This webinar shared the topics on which OHE research had the biggest impact in 2024 including drug shortages and vaccines, whilst looking ahead to 2025.

This panel brings together leading researchers to explore how health economics can inform policy design in the context of the climate crisis. Rather than proposing new evaluative paradigms, the ...

The US spends significantly more on healthcare per person than other wealthy countries. H.R. 3 is a recent policy proposal aimed at reducing national spending on prescription drugs, one component of ...

Obstructive sleep apnoea (OSA) is the temporary cessation of breathing during sleep because of a narrowing or closure of the pharyngeal airway. Untreated OSA can result in daytime sleepiness that ...

OHE Research Paper 19/02: The combination of rising drug costs in the US and increasing financial stress for individual patients has triggered intense national concern. One target has come under ...

Next-generation sequencing (NGS) generates comprehensive and actionable information on molecular tumour profiles. But despite recommendations for the use of NGS in lung cancer, and support for its ...

Based on an OHE lunchtime seminar by Professor Henry Grabowski, this seminar briefing explores the lessons learned from Europe’s experience with biosimilars, and provides an analysis of how the US ...

After the shock caused by the first wave of COVID-19, discovering vaccines against the virus and administering them quickly to the population became the utmost priority worldwide, especially once ...

The purpose of this research is to identify the attributes to include in a value framework for orphan medicinal products (OMPs), determine their relative importance using a multi-criteria decision ...

This report contributes to the understanding of people’s proximity to dementia (e.g., people with dementia and their carers forecast) and so the potential future number of people who will be impacted ...

Although the science underlying drug development has evolved, there has been little change in how we pay for them. As more and more medicines come to market with multiple indications (or even more ...